Parents view their fetus using 3D virtual reality

Ultrasound appointment are a momentous occasion for many parents to be. But researchers have developed a method that may allow parents to view their fetus in three dimensions.

"The 3D fetal models combined with virtual reality immersive technologies may improve our understanding of fetal anatomical characteristics and can be used for educational purposes and as a method for parents to visualize their unborn baby," said study co-author Heron Werner Jr., MD, PhD, from the Clínica de Diagnóstico por Imagem, in Rio de Janeiro, who will present such information next week at the Radiological Society of North America (RSNA) in Chicago.

Utilizing the power of MRI and ultrasounds, researchers have developed a realistic 3D virtual reality of the growing fetus. The 3D virtual reality shows the entire structure of the fetus, including a view of the respiratory tract that physicians can use as an indicator for health. Researchers used the Oculus Rift 2 headset to show parents their fetuses down to their fingers.

"The experience with the Oculus Rift has been wonderful," said Werner. "It provides fetal images that are sharper and clearer than ultrasound and MR images viewed on a traditional display. The physicians can have access to an immersive experience on the clinical case that they are working on, having the whole internal structure of the fetus in 3D in order to better visualize and share the morphological information."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.